# EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis

> **NCT02309411** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 46 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)

## Key facts

- **NCT ID:** NCT02309411
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-15
- **Primary completion:** 2017-04-05
- **Final completion:** 2017-04-05
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2018-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02309411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02309411, "EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02309411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*